MONDAY, Nov. 5 (HealthDay News) -- Approval of the anti-clotting drug Xarelto (rivaroxaban) has been expanded by the U.S. Food and Drug Administration to include treating deep vein thrombosis (DVT) or pulmonary embolism.
DVT occurs when a blood clot forms in a vein deep in the body. If a clot breaks away and travels to an artery in the lungs, it becomes a potentially deadly condition called a pulmonary embolism.
Xarelto was approved last year to treat clots stemming from knee or hip replacement and to lessen the risk of stroke in people with a form of abnormal heart rhythm called non-valvular atrial fibrillation.
The drug's newest approvals were given based on clinical studies involving 9,478 people, the FDA said in a news release. As with other anti-clotting drugs, bleeding is the most common side effect.
Xarelto is produced by Janssen Pharmaceuticals, based in Raritan, N.J.
The FDA has more about this approval.
be well, feel better
To squash stress and renew your energy, take five.
Simple ways to avoid a cook's nightmare.
Find out which ones help you cheer up, increase libido, lose weight and build muscle.
A guy’s guide to health, from early adulthood to retirement and beyond.
These nutrition solutions do everything from clear your skin to supercharge your mood.
Stay lean and look fabulous with our complete exercise, food and motivation plan.
Fascinating clues to your health that your mirror can provide
What do these items have in common? They could be making your head hurt.